<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02824068</url>
  </required_header>
  <id_info>
    <org_study_id>Po001-STIG</org_study_id>
    <nct_id>NCT02824068</nct_id>
  </id_info>
  <brief_title>Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months (STIG-Pompe-Study)</brief_title>
  <acronym>STIG</acronym>
  <official_title>Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LMU Klinikum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LMU Klinikum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-term outcome in late-onset Pompe disease treated beyond 36 months (ATBIG-Pompe-Study), a&#xD;
      multicenter, multinational, longitudinal, non-interventional observational study in subjects,&#xD;
      at least 8 years old, diagnosed with late-onset Pompe disease retrospectively and&#xD;
      prospectively collects data to understand clinical progression in terms of muscle and&#xD;
      respiratory function, and clinical symptomology treated with alglucosidase alfa more than 36&#xD;
      months in 100 subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The presentation and course of late-onset Pompe disease is much less foreseeable than the&#xD;
      classic infantile form. Some patients experience a rapid worsening in skeletal muscle&#xD;
      function leading to loss of ambulation and respiratory failure, while others progress less&#xD;
      rapidly. So there is a more inconstant response to treatment in skeletal muscle and lung&#xD;
      function in the long-term. Therefore, an unmet clinical need is the collection and analysis&#xD;
      of long-term data of rhGAA enzyme replacement therapy (ERT) in late-onset Pompe disease&#xD;
      patient aged 8 years and older. The principal goal of our investigator driven study is to&#xD;
      gain conclusive insight in long-term outcome data beyond 36 months up to 10 years of ERT&#xD;
      treatment. In addition we will collect biological samples from all patients for a future&#xD;
      biomarker study including gene modifier search by genome and RNA seq (not part of this&#xD;
      proposal). This study may provide clinicians and researchers with a better understanding of&#xD;
      late-onset Pompe disease under long-term treatment, to the benefit of all patients affected&#xD;
      with late-onset Pompe disease, as well as, individuals and families with related diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in muscle function</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the degree of change in muscle function over time in patients with Pompe disease. % change in the 6-minute walking test (normal 600m in six minutes) between 0, 6 and 12 months of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>data collection on survival, death and reason of deaths</measure>
    <time_frame>12 months</time_frame>
    <description>data collection on survival, death and reason of deaths during the full study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in forced vital capacity (FVC)</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the degree of change in lung function over time in patients with Pompe disease by % change of FVC in sitting and supine body position between 0, 6, and 12 months of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in minimal inspiratory pressure (MIP)</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the degree of change in lung function over time in patients with Pompe disease: % change in minimal inspiratory pressure between 0, 6 and 12months of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in maximal expiratory pressure (MEP)</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the degree of change in lung function over time in patients with Pompe disease % change in maximal expiratory pressure between 0, 6 and 12months of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in loss of ambulation</measure>
    <time_frame>12 months</time_frame>
    <description>% of patients with loss of ambulation at 12 months of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in Medical Research Council (MRC) Scale for Muscle Strength</measure>
    <time_frame>12 months</time_frame>
    <description>% of patients with changes in 5-point MRC (scale data at 12 months of the study</description>
  </secondary_outcome>
  <enrollment type="Actual">112</enrollment>
  <condition>Pompe Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glucosidase alfa</intervention_name>
    <description>Long-term use in an observational study of licenced drug</description>
    <other_name>Myozyme</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine samples to be collected for exploratory research, Genetic/Genomic testing is&#xD;
      optional requiring specific consent&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Late-onset Pompe patients, aged over 8 years with at least 36 months of glucosiase alfa&#xD;
        treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Late-onset Pompe patients, aged over 8 years.&#xD;
&#xD;
          -  The patient is willing and able to provide signed informed consent.&#xD;
&#xD;
          -  The patient (and patient's legal guardian if patient is under 18 years of age) must&#xD;
             have the ability to comply with the clinical protocol.&#xD;
&#xD;
          -  Long-term Myozyme treatment beyond 36 months.&#xD;
&#xD;
          -  Known GAA genotype.&#xD;
&#xD;
          -  GAA activity (Dried blood spot testing, or other methods).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - The patient is concurrently participating in another clinical study using Myozyme or&#xD;
             other treatment.&#xD;
&#xD;
          -  The patient, in the opinion of the Investigator, is unable to adhere to the&#xD;
             requirements of the study.&#xD;
&#xD;
          -  The patient has clinically significant organic disease (with the exception of symptoms&#xD;
             relating to Pompe disease), including clinically significant cardiovascular, hepatic,&#xD;
             pulmonary, neurologic, or renal disease, or other medical condition, serious&#xD;
             intercurrent illness, or extenuating circumstance that, in the opinion of the&#xD;
             Investigator, precludes participation in the study or potentially decreases survival.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedikt Schoser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich-Baur-Institute, Dep. of Neurology Klinikum der Universitaet Muenchen Munich, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friedrich-Baur-Institute, Dep. of Neurology Klinikum der Universitaet Muenchen Munich, Germany</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>5. Department of Clinical and Experimental Medicine, Reference Center for Rare Neuromuscular Disorders, University of Messina, Italy</name>
      <address>
        <city>Messina</city>
        <state>Sicily</state>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital Taipei</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Taiwan</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Brazil</country>
  </removed_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>July 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2016</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LMU Klinikum</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Benedikt Schoser</investigator_full_name>
    <investigator_title>Head of the interdisciplinar neuromuscular unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patients have the right to get their own data set after the end of the study</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>open access via the publication given link below</ipd_time_frame>
    <ipd_access_criteria>open access</ipd_access_criteria>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://link.springer.com/article/10.1007/s00415-021-10409-9</doc_url>
      <doc_comment>Open access of the full study report can be downloaded under above webpage of the Journal of Neurology</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

